keyword
https://read.qxmd.com/read/38585464/a-comprehensive-review-on-novel-lipid-based-nano-drug-delivery
#1
REVIEW
Sonam Suresh Godase, Nilesh Shrikant Kulkarni, Shashikant Nivrutti Dhole
Novel drug delivery system opens the doors towards nano/micro formulation strategies to overcome the challenges associated with the poorly soluble and permeable drugs. Lipid based nanoparticles are widely accepted that includes liposomes, niosomes and micelles which are FDA approved. Such lipid based drug delivery allows delivery for natural phytoconstituents, biopharmaceutical classification system (BCS) class II and class IV drugs are effectively delivered to improve its solubility, permeability and bioavailability...
March 2024: Advanced Pharmaceutical Bulletin
https://read.qxmd.com/read/38559693/blood-glucose-monitoring-devices-for-type-1-diabetes-a-journey-from-the-food-and-drug-administration-approval-to-market-availability
#2
REVIEW
Rahul Mittal, Nicole Koutras, Jonathan Maya, Joana R N Lemos, Khemraj Hirani
Blood glucose monitoring constitutes a pivotal element in the clinical management of Type 1 diabetes (T1D), a globally escalating metabolic disorder. Continuous glucose monitoring (CGM) devices have demonstrated efficacy in optimizing glycemic control, mitigating adverse health outcomes, and augmenting the overall quality of life for individuals afflicted with T1D. Recent progress in the field encompasses the refinement of electrochemical sensors, which enhances the effectiveness of blood glucose monitoring...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38535119/adme-gene-related-pharmacogenomic-labeling-of-fda-approved-drugs-comparison-with-clinical-pharmacogenetics-implementation-consortium-cpic-evidence-levels
#3
JOURNAL ARTICLE
Subrata Deb, Robert Hopefl, Anthony Allen Reeves, Dena Cvetkovic
Pharmacogenomics (PGx) can facilitate the transition to patient-specific drug regimens and thus improve their efficacy and reduce toxicity. The aim of this study was to evaluate the overlap of PGx classification for drug absorption, distribution, metabolism, and elimination (ADME)-related genes in the U.S. Food and Drug Administration (FDA) PGx labeling and in the Clinical Pharmacogenetics Implementation Consortium (CPIC) database. FDA-approved drugs and PGx labeling for ADME genes were identified in the CPIC database...
February 20, 2024: Medicines (Basel, Switzerland)
https://read.qxmd.com/read/38491743/an-update-on-clinical-trials-for-cutaneous-lupus-erythematosus
#4
REVIEW
Lillian Xie, Lais Lopes Almeida Gomes, Caroline J Stone, Daniella Forman Faden, Victoria P Werth
Cutaneous lupus erythematosus (CLE) comprises dermatologic manifestations that may occur independently or with systemic lupus erythematosus (SLE). Despite advancements in refining CLE classification, establishing precise subtype criteria remains challenging due to overlapping presentations and difficulty in distinguishing morphology. Current treatments encompass preventive measures, topical therapies, and systemic approaches. Hydroxychloroquine and glucocorticoids are the sole US Food and Drug Administration (FDA)-approved medications for CLE, with numerous off-label treatments available...
March 15, 2024: Journal of Dermatology
https://read.qxmd.com/read/38432353/generation-of-a-drug-induced-renal-injury-list-to-facilitate-the-development-of-new-approach-methodologies-for-nephrotoxicity
#5
JOURNAL ARTICLE
Skylar Connor, Ting Li, Yanyan Qu, Ruth A Roberts, Weida Tong
Drug-induced renal injury (DIRI) causes >1.5 million adverse events annually in the USA alone. Although standard biomarkers exist for DIRI, they lack the sensitivity or specificity to detect nephrotoxicity before the significant loss of renal function. In this study, we describe the creation of DIRIL - a list of drugs associated with DIRI and nephrotoxicity - from two literature datasets with DIRI annotation, confirmed using FDA drug labeling. DIRIL comprises 317 orally administered drugs covering all 14 anatomical, therapeutic and chemical (ATC) classification categories...
March 1, 2024: Drug Discovery Today
https://read.qxmd.com/read/38423763/single-cell-analysis-of-rohon-beard-neurons-implicates-fgf-signaling-in-axon-maintenance-and-cell-survival
#6
JOURNAL ARTICLE
Adam M Tuttle, Lauren N Miller, Lindsey J Royer, Hua Wen, Jimmy J Kelly, Nicholas L Calistri, Laura M Heiser, Alex V Nechiporuk
Peripheral sensory neurons are a critical part of the nervous system that transmit a multitude of sensory stimuli to the central nervous system. During larval and juvenile stages in zebrafish, this function is mediated by Rohon-Beard somatosensory neurons (RBs). RBs are optically accessible and amenable to experimental manipulation, making them a powerful system for mechanistic investigation of sensory neurons. Previous studies provided evidence that RBs fall into multiple subclasses; however, the number and molecular make up of these potential RB subtypes have not been well defined...
February 29, 2024: Journal of Neuroscience
https://read.qxmd.com/read/38407147/safety-profile-of-selective-serotonin-reuptake-inhibitors-in-real-world-settings-a-pharmacovigilance-study-based-on-fda-adverse-event-reporting-system
#7
JOURNAL ARTICLE
Yi Zhao, Yuzhou Zhang, Lin Yang, Kanghuai Zhang, Sha Li
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed agents to treat depression. Considering the growth in antidepressant prescription rates, SSRI-induced adverse events (AEs) need to be comprehensively clarified. OBJECTIVE: This study was to investigate safety profiles and potential AEs associated with SSRIs using the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: A retrospective pharmacovigilance analysis was conducted using the FAERS database, with Open Vigil 2...
February 26, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38371270/assessment-of-the-u-s-food-and-drug-administration-s-risk-evaluation-and-mitigation-strategy-rems-for-prasugrel-effient-a-narrative-review
#8
JOURNAL ARTICLE
Thomas Metkus, Jill Curran, Shanshan Lin, Dima M Qato, G Caleb Alexander
BACKGROUND: Prasugrel, first approved in 2009, was subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to mitigate the risk of bleeding associated with its use. METHODS: We performed a narrative review of FDA documents obtained through a Freedom of Information Act request. Document classification and primary evidence extraction was performed by three authors (TM, JC, and SL). RESULTS: The prasugrel REMS consists of a medication guide and a communication plan...
February 2024: American heart journal plus: cardiology research and practice
https://read.qxmd.com/read/38365980/a-bayesian-approach-for-investigating-the-pharmacogenetics-of-combination-antiretroviral-therapy-in-people-with-hiv
#9
JOURNAL ARTICLE
Wei Jin, Yang Ni, Amanda B Spence, Leah H Rubin, Yanxun Xu
Combination antiretroviral therapy (ART) with at least three different drugs has become the standard of care for people with HIV (PWH) due to its exceptional effectiveness in viral suppression. However, many ART drugs have been reported to associate with neuropsychiatric adverse effects including depression, especially when certain genetic polymorphisms exist. Pharmacogenetics is an important consideration for administering combination ART as it may influence drug efficacy and increase risk for neuropsychiatric conditions...
February 14, 2024: Biostatistics
https://read.qxmd.com/read/38348394/real-world-drug-treatment-models-for-pregnancy-complicated-with-urinary-tract-infection-in-china-from-2018-to-2022-a-cross-section-analysis
#10
JOURNAL ARTICLE
Jing Jin, Changyan Li, Yuqing He, Jiaqian Pan, JiaLei Zhu, Jing Tang
Objective: Urinary tract infection (UTI) is common in pregnant women. The selection of anti-infection plans during pregnancy must take into account the dual factors of patient pregnancy status and urinary tract infection anti-infection treatment, as well as the efficacy, cost, risk, and potential adverse reactions associated with each method applied to individual patients. Consequently, there are numerous drugs from which to choose; presently, there is no unified conclusion regarding the choice of drug therapy, and there is a lack of long-term drug treatment for UTI during pregnancy...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38332182/beyond-the-510-k-the-regulation-of-novel-moderate-risk-medical-devices-intellectual-property-considerations-and-innovation-incentives-in-the-fda-s-de-novo-pathway
#11
JOURNAL ARTICLE
Mateo Aboy, Cristina Crespo, Ariel Stern
Moderate-risk medical devices constitute 99% of those that have been regulated by the U.S. Food and Drug Administration (FDA) since it gained authority to regulate medical technology nearly five decades ago. This article presents an analysis of the interaction between the 510(k) process -the historically dominant path to market for most medical devices- and the De Novo pathway, a more recent alternative that targets more novel devices, including those involving new technologies, diagnostics, hardware, and software...
February 8, 2024: NPJ Digital Medicine
https://read.qxmd.com/read/38314095/microrna-centered-theranostics-for-pulmoprotection-in-critical-covid-19
#12
JOURNAL ARTICLE
Manel Perez-Pons, Marta Molinero, Iván D Benítez, María C García-Hidalgo, Shambhabi Chatterjee, Christian Bär, Jessica González, Antoni Torres, Ferran Barbé, David de Gonzalo-Calvo
Elucidating the pathobiological mechanisms underlying post-acute pulmonary sequelae following SARS-CoV-2 infection is essential for early interventions and patient stratification. Here, we investigated the potential of microRNAs (miRNAs) as theranostic agents for pulmoprotection in critical illness survivors. Multicenter study including 172 ICU survivors. Diffusion impairment was defined as a lung-diffusing capacity for carbon monoxide (DLCO ) <80% within 12 months postdischarge. A disease-associated 16-miRNA panel was quantified in plasma samples collected at ICU admission...
March 12, 2024: Molecular Therapy. Nucleic Acids
https://read.qxmd.com/read/38294346/food-drug-effects-and-pediatric-drug-development-studies-submitted-to-the-us-food-and-drug-administration-2012-2022
#13
JOURNAL ARTICLE
Kayla R Tunehag, Blessy George, Sherbet Samuels, Karen Vo, Vikram Arya, Gelareh Abulwerdi, Gilbert J Burckart
Food effect (FE) studies characterize food-drug interactions that may alter the efficacy or safety of a drug, but these studies are not conducted in pediatric patients. Pediatric patients have substantial physiologic, anatomic, and dietary differences from adults, which may result in differences in their FE considerations. Therefore, the objective of this study was to identify oral drug products approved for use in pediatric patients aged <6 years with an FE observed in adults. Additional objectives were to summarize the therapeutic areas, pharmacokinetic effects, and labeling instructions that resulted from these studies...
January 31, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38287066/harnessing-machine-learning-to-find-synergistic-combinations-for-fda-approved-cancer-drugs
#14
JOURNAL ARTICLE
Tarek Abd El-Hafeez, Mahmoud Y Shams, Yaseen A M M Elshaier, Heba Mamdouh Farghaly, Aboul Ella Hassanien
Combination therapy is a fundamental strategy in cancer chemotherapy. It involves administering two or more anti-cancer agents to increase efficacy and overcome multidrug resistance compared to monotherapy. However, drug combinations can exhibit synergy, additivity, or antagonism. This study presents a machine learning framework to classify and predict cancer drug combinations. The framework utilizes several key steps including data collection and annotation from the O'Neil drug interaction dataset, data preprocessing, stratified splitting into training and test sets, construction and evaluation of classification models to categorize combinations as synergistic, additive, or antagonistic, application of regression models to predict combination sensitivity scores for enhanced predictions compared to prior work, and the last step is examination of drug features and mechanisms of action to understand synergy behaviors for optimal combinations...
January 29, 2024: Scientific Reports
https://read.qxmd.com/read/38269549/the-regulatory-challenges-of-placing-dietary-ingredients-on-the-european-and-us-market
#15
REVIEW
M J Tallon, D S Kalman
The DSHEA is 30 years old and its place in providing legitimate protections for public health through relevant agency oversight has created a patchwork of legal and scientific requirements. In contrast, the European Union has rules on supplements and permitted ingredients. Given the context of a global supply chain for food ingredients any conflict between the legality of ingredients between the U.S/EU can inhibit the economic viability of international trade. The purpose of this review is to contrast these different systems of legislative oversight...
January 25, 2024: Journal of Dietary Supplements
https://read.qxmd.com/read/38247407/psilocybin-an-effective-treatment-for-major-depressive-disorder-in-adults-a-systematic-review
#16
REVIEW
Tessa Watford, Naqash Masood
Psilocybin is a classical psychedelic which has been utilised for healing purposes for millenia. However, with its classification as a Schedule I substance, research into this compound is scarce with few FDA-approved clinical studies. Despite this, profound findings into its antidepressant effects (largely through its action on 5-HT1a receptors) in mental illnesses such as major depressive disorder have rapidly increased interest back into their potential therapeutic benefits. This systematic review provides an analysis of the studies examining the clinical use of psilocybin for major depressive disorder...
February 29, 2024: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://read.qxmd.com/read/38236123/multiple-keratinocytic-cancers-after-enalapril-losartan-intake-potential-links-to-drug-mediated-nitrosogenesis-carcinogenesis-melolabial-advanced-flap-and-undermining-surgery-as-optimal-therapeutic-approach
#17
JOURNAL ARTICLE
G Tchernev
According to scientific databases, nitrosogenesis and carcinogenesis have been inextricably linked for decades and are undoubtedly one of the most serious causes of cancer induction (not only skin cancer) known to humankind.Some of the most potent modifiers of human DNA turn out to be numerous, known since the last century, difficult to classify as carcinogenic potency, yet available for decades as additional, unregulated, often undisclosed ingredients in about (currently) 300 drugs used by at least 5 billion patients worldwide...
November 2023: Georgian Medical News
https://read.qxmd.com/read/38233388/pharmacogenomic-biomarker-information-on-drug-labels-of-the-spanish-agency-of-medicines-and-sanitary-products-evaluation-and-comparison-with-other-regulatory-agencies
#18
JOURNAL ARTICLE
María Estévez-Paredes, M Carmen Mata-Martín, Fernando de Andrés, Adrián LLerena
This work aimed to analyse the pharmacogenetic information in the Spanish Drug Regulatory Agency (AEMPS) Summary of Products Characteristics (SmPC), evaluating the presence of pharmacogenetic biomarkers, as well as the associated recommendations. A total of 55.4% of the 1891 drug labels reviewed included information on pharmacogenetic biomarker(s). Pharmacogenomic information appears most frequently in the "antineoplastic and immunomodulating agents", "nervous system", and "cardiovascular system" Anatomical Therapeutic Chemical groups...
January 17, 2024: Pharmacogenomics Journal
https://read.qxmd.com/read/38227161/network-based-drug-repurposing-identifies-small-molecule-drugs-as-immune-checkpoint-inhibitors-for-endometrial-cancer
#19
JOURNAL ARTICLE
Faheem Ahmed, Anupama Samantasinghar, Wajid Ali, Kyung Hyun Choi
Endometrial cancer (EC) is the 6th most common cancer in women around the world. Alone in the United States (US), 66,200 new cases and 13,030 deaths are expected to occur in 2023 which needs the rapid development of potential therapies against EC. Here, a network-based drug-repurposing strategy is developed which led to the identification of 16 FDA-approved drugs potentially repurposable for EC as potential immune checkpoint inhibitors (ICIs). A network of EC-associated immune checkpoint proteins (ICPs)-induced protein interactions (P-ICP) was constructed...
January 16, 2024: Molecular Diversity
https://read.qxmd.com/read/38201592/clinical-biofluid-assays-for-prostate-cancer
#20
REVIEW
Talaibek Borbiev, Indu Kohaar, Gyorgy Petrovics
This mini review summarizes the currently available clinical biofluid assays for PCa. The second most prevalent cancer worldwide is PCa. PCa is a heterogeneous disease, with a large percentage of prostate tumors being indolent, and with a relatively slow metastatic potential. However, due to the high case numbers, the absolute number of PCa-related deaths is still high. In fact, it causes the second highest number of cancer deaths in American men. As a first step for the diagnosis of PCa, the PSA test has been widely used...
December 28, 2023: Cancers
keyword
keyword
114374
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.